title: [Desmopressin in the Treatment of Enuresis: Is Lyophilisate Superior to Tablets?]
abstract: Background:Prognosis of MNE is good when adequate treatment starts in a timely manner. First-line treatment for monosymptomatic nocturnal enuresis (MNE) includes desmopressin (Grade A/Level 1 recommendation from the ICI). Missing or insufficient response to pharmacological treatment can be caused by incomplete compliance, but might also be associated with differences in bioavailability from the tablet form. This prospective, non-interventional study was designed to compare desmopressin tablets to the newer ,,melt'' formulation, also known as lyophilisate or orally disintegrating tablet (ODT). The primary endpoint of this study was the patients'/parents' acceptance; the secondary end point was a decrease in the number of wet nights.Materials and Methods:Each of the scheduled 100 participating doctors had to recruit two MNE candidates, one for each treatment group, with a planned total of 200 participants. At the end of the treatment period, treatment satisfaction, difficulties in taking the medication, forgotten doses and treatment success were reported.Results:In total, 134 patients were included (49 on tablet and 84 on melt). Difficulties in taking the medication and forgotten doses were significantly less with the melt than with the tablet formulation. Treatment satisfaction was better with melt. After the 3 months study, the number of wet nights was considerably reduced in both groups. With lyophilisate, a statistically significant greater reduction in wet nights was recorded as early as 2 weeks after starting the treatment.Conclusion:Desmopressin as orally disintegrating tablets is an effective treatment and is associated with improved patient compliance.
authors.affiliation: Klinik für Kinder- und Jugendmedizin 1, UKSH Universitätsklinikum Schleswig-Holstein, Kiel.
authors.forename: S
authors.initials: S
authors.lastname: Schulz-Jürgensen
authors.affiliation: Medical Writer, Hamburg.
authors.forename: B
authors.initials: B
authors.lastname: Feldmann
authors.affiliation: Klinik für Kinder- und Jugendmedizin 1, UKSH Universitätsklinikum Schleswig-Holstein, Kiel.
authors.forename: P
authors.initials: P
authors.lastname: Eggert
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D003258:Consumer Behavior; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004775:Enuresis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005612:Freeze Drying; D006801:Humans; D008297:Male; D010349:Patient Compliance; D013607:Tablets; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
chemical_list: D013607:Tablets; D003894:Deamino Arginine Vasopressin